↓ Skip to Main Content
Thasso

Thasso

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in | Register

Main Navigation

  • englishenglish
    • englishenglish
    • françaisfrançais
    • deutschdeutsch
    • italianoitaliano
    • españolespañol
    • portuguêsportuguês
  • thasso
  • thasso: post
  • thasso: interactions
    • thasso: community
    • thasso: video chat
    • thasso: simple chat
    • thasso: patient groups
    • thasso: forum
    • thasso: online meetings (ZOOM)
  • thasso: resources
    • theragenomics: useful links
    • theragenomics: survey at thasso
      • survey participants
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: targeted therapies
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • theragenomics: videos
    • drugs: interactions
    • drugs: general information
    • drugs: adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
  • thasso: academy
    • health authorities
      • European Medicines Agency (EMA)
      • American Food & Drug Administration (FDA)
      • Swissmedic
      • FDA Ghana
      • NAFDAC Nigeria
      • CDSCO India
      • The Medicines Control Council (MCC), South Africa
      • China Food & Drug Administration (CFDA)
      • Health Canada
    • public domain
      • Clinical Pharmacogenetics Implementation Consortium
      • ACMG Genetic Test Fact Sheets
      • Public Health Genomics Knowledge Base
      • The Human Diagnosis Project
      • Phenotypes And Genotypes Database
      • Genetic Alliance UK
      • Genetics Generation
      • Front Line Genomics
      • Alliance for Cancer Gene Therapy (ACGT)
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
      • European Patient Forum
      • Uppsala Monitoring Center
      • World Health Organisation (WHO)
      • von Hippel Lindau Syndrome (VHL)
      • Cerebral Palsy Symptoms
      • Mesothelioma Fund
      • Multiple Myeloma Research Foundation
      • Open Source Pharma (OSP, Medicine for All)
    • theragenomics worldwide
      • The Human Heredity and Health in Africa (H3Africa)
      • The Asia Cohort Consortium
      • GenomeAsia 100K
    • patient & consumer health
      • ThinkGenetic
      • Consumer Health Labs
      • Exercise & Heart Disease
      • UCSF: Eating right for your heart
      • Hormones Matter
      • Living with Arthritis
      • Living with Cannabis
      • Yum of China (Foods)
    • digital therapeutics in theragenomic medicine
      • Digital Therapeutics Alliance (DTA)
      • Digital Health Alliance
    • miscellaneous
      • Partners Health Care / Personalized Medicine
      • Worst Pills / Best Pills
      • Pharmagenomics Research Network
      • Mayo Clinic: Personalized Medicine
      • Patient Power
      • Patient Opinion (UK)
      • Drug Injury Watch (Tom Lamb)
      • Ways To Fund Cancer Treatments
      • MedScape India
      • Swiss Academy of Medical Sciences
      • IDICAP: An Integrated Drug Intervention for Cancer Panel
      • PanDrugs
      • Soccer Genomics
    • companies
      • Moderna
      • BionTech
      • FDNA (Face2Gene Home)
      • IONIS Pharmaceuticals
      • Boehringer Ingelheim Home
      • Bristol-Myers Squipp Home
      • Glaxo Home
      • Novartis Home
      • Roche Home
      • AstraZeneca Home
      • Merck Home
      • Gilead Home
      • Takeda Home
      • Janssen Home
      • Novo Nordisk Home
      • Amgen Home
    • products
      • Axicabtagene ciloleucel (Yescarta)
      • Ledipasvir/Sofosbuvir (Harvoni)
      • Sofosbuvir (Sovaldi)
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Sekukinumab (Cosentyx)
      • Rivaroxaban (Xarelto)
      • Valsartan/Amlodipin/HCT (Exforge/HCT)
      • Aripiprazole (Abilify)
      • Rosuvastatin (Crestor)
      • Flibanserin (Addyi)
      • Onasemnogene abeparvovec-xioi (Zolgensma)
      • Voretigene neparvovec (Luxturna)
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • disclaimers
    • policies
    • contact
  • donations $
  • Cookie Policy (EU)
Home › Posts tagged Sitaxentan [Thelin]

Tag: Sitaxentan [Thelin]

Sitaxentan [Thelin] to be withdrawn from market worldwide due to cases of unpredictable serious liver injury

By Joseph Gut - thasso Posted on December 13, 2010 Posted in Adverse Drug Reaction [ADR], Market Withdrawal Tagged with Ambrisentan [Letairis], Ambrisentan [Volibris], Bosentan [Tracleer], Drug Induced Liver Injury (DILI), Pulmonary Arterial Hypertension (PAH), Sildenafil [Revatio], Sitaxentan [Thelin], Tadalafil [Adcirca], ThassoBase, Theragenomics Associates

December 13, 2010 – We learn today that the European Medicines Agency (EMEA) has been informed of Pfizer’s decision to voluntarily withdraw Sitaxentan [Thelin] from the market worldwide further to new information on two cases of fatal liver injury. Pfizer …

Sitaxentan [Thelin] to be withdrawn from market worldwide due to cases of unpredictable serious liver injury Read more »

In/Out

  • Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

 

RSS FDA press releases

  • FDA Roundup: March 17, 2023 March 17, 2023
  • FDA Denies Marketing of Two Vuse Solo Menthol E-Cigarette Products March 17, 2023
  • FDA Authorizes Copenhagen Classic Snuff to be Marketed as a Modified Risk Tobacco Product March 16, 2023
  • Coronavirus (COVID-19) Update: FDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age March 14, 2023
  • FDA Roundup: March 14, 2023 March 14, 2023

RSS FDA MedWatch

  • 2023 Medical Device Recalls March 17, 2023
  • Datascope/Getinge Recalls Certain Cardiosave Hybrid and Rescue Intra-Aortic Balloon Pumps (IABP) for Risk of Unexpected Shutdown Coiled Cord Connection Failure March 17, 2023
  • Baxter Issues Urgent Medical Device Correction for LIFE2000 Ventilation System Due to Potential for Patient Desaturation When Connected with an Oxygen Concentrator March 10, 2023
  • Breast Implants: Reports of Squamous Cell Carcinoma and Various Lymphomas in Capsule Around Implants: FDA Safety Communication March 8, 2023
  • UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants - FDA Safety Communication March 8, 2023

RSS EMA Press releases

  • EMA Management Board: highlights of March 2023 meeting, MB, 17/03/2023 March 17, 2023
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13 - 16 March 2023, PRAC, 17/03/2023 March 17, 2023
  • Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 December 2022, CVMP, 09/12/2022 March 15, 2023
  • Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 February 2023, CVMP, 17/02/2023 March 10, 2023
  • EMA pilots scientific advice for certain high-risk medical devices, , 27/02/2023 February 27, 2023

RSS random genetics

  • Step forward in gene therapy to treat cause of sudden cardiac arrest in athletes March 18, 2023
    University of Utah Health scientists have corrected abnormal heart rhythms in mice by restoring healthy levels of a protein that heart cells need to establish connections with one another. That protein, GJA1-20k, is underproduced in people with a genetic condition called arrhythmogenic cardiomyopathy, one of the leading causes of sudden cardiac arrest in athletes under […]
  • Study: Senescence-associated exosomes transfer fibrosis to neighboring cells March 17, 2023
    A new research paper, titled "Senescence-associated exosomes transfer miRNA-induced fibrosis to neighboring cells," was published in Aging.
  • A genetic predisposition may protect some night shift workers against sleep loss March 17, 2023
    Up to 25% of public sector employees in the UK do some form of night work. Similar numbers in other countries engage in shift work. But increasing evidence shows night work and persistent circadian rhythm disruption is a serious risk factor for health conditions, including depression, heart disease and type-2 diabetes.
  • Research reveals Orkney cancer gene link—now testing will take place March 17, 2023
    One in 100 people who have grandparents from Orkney have a gene variant that causes a higher risk of developing breast and ovarian cancer, a study has found.
  • New gene-editing technique reverses vision loss in mice March 17, 2023
    Researchers in China have successfully restored the vision of mice with retinitis pigmentosa, one of the major causes of blindness in humans. The study, to be published March 17 in the Journal of Experimental Medicine, uses a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing […]

Recent Comments

  • Joseph Gut - thasso on Is there pre-emptive genotyping to avoid adverse drug effects (ADRs)?: “Just testing. https://www.alphamannosidosis.com/en/for-patients-caregivers/disease-information/?utm_source=google&utm_medium=cpc&utm_campaign=AlphamannSearch_Paziente2020&gclid=EAIaIQobChMI2Pv7wNaC_AIVWud3Ch1J8AMPEAAYAiAAEgJGI_D_BwE/” Dec 18, 08:50
  • Joseph Gut - thasso on Including Africa in the research on rare genetic diseases: A must!: “The genetic diversity of African populations with respect to rare genetic diseases will help to better understand the mechanisms behind…” Dec 18, 04:09
  • Joseph Gut - thasso on The sixth sense: Are there genes associated with it?: “Does this now work as intended?” Dec 18, 03:55
  • David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
  • Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2023 Thasso | Powered by Responsive Theme
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}